Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Patterns of recurrence after radiation therapy for high-risk neuroblastoma

  • Jo, Ji Hwan (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Ahn, Seung Do (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Koh, Minji (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Jong Hoon (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Sang-wook (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Song, Si Yeol (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Yoon, Sang Min (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Young Seok (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Su Ssan (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Park, Jin-hong (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Jung, Jinhong (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Choi, Eun Kyung (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2019.06.26
  • Accepted : 2019.09.16
  • Published : 2019.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To investigate the patterns of recurrence in patients with neuroblastoma treated with radiation therapy to the primary tumor site. Materials and Methods: We retrospectively analyzed patients with high-risk neuroblastoma managed with definitive treatment with radiation therapy to the primary tumor site between January 2003 and June 2017. These patients underwent three-dimensional conformal radiation therapy or intensity-modulated radiation therapy. A total of 14-36 Gy was delivered to the planning target volume, which included the primary tumor bed and the selected metastatic site. The disease stage was determined according to the International Neuroblastoma Staging System (INSS). We evaluated the recurrence pattern (i.e., local or systemic), progression-free survival, and overall survival. Results: A total of 40 patients with high-risk neuroblastoma were included in this study. The median patient age was 4 years (range, 1 to 11 years). Thirty patients (75%) had INSS stage 4 neuroblastoma. At the median follow-up of 58 months, there were 6 cases of local recurrence and 10 cases of systemic recurrence. Among the 6 local failure cases, 4 relapsed adjacent to the radiation field. The other 2 relapsed in the radiation field (i.e., para-aortic and retroperitoneal areas). The main sites of distant metastasis were the bone, lymph nodes, and bone marrow. The 5-year progression-free survival was 70.9% and the 5-year overall survival was 74.3%. Conclusion: Radiation therapy directed at the primary tumor site provides good local control. It seems to be adequate for disease control in patients with high-risk neuroblastoma after chemotherapy and surgical resection.

Keywords

References

  1. Gurney JG, Ross JA, Wall DA, Bleyer WA, Severson RK, Robison LL. Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol 1997;19:428-32. https://doi.org/10.1097/00043426-199709000-00004
  2. Laverdiere C, Liu Q, Yasui Y, et al. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009;101:1131-40. https://doi.org/10.1093/jnci/djp230
  3. Woods WG, Tuchman M, Bernstein ML, et al. Screening for neuroblastoma in North America: 2-year results from the Quebec Project. Am J Pediatr Hematol Oncol 1992;14:312-9. https://doi.org/10.1097/00043426-199211000-00006
  4. Castleberry RP, Kun LE, Shuster JJ, et al. Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. J Clin Oncol 1991;9:789-95. https://doi.org/10.1200/JCO.1991.9.5.789
  5. Wolden SL, Gollamudi SV, Kushner BH, et al. Local control with multimodality therapy for stage 4 neuroblastoma. Int J Radiat Oncol Biol Phys 2000;46:969-74. https://doi.org/10.1016/S0360-3016(99)00399-5
  6. Kushner BH, Wolden S, LaQuaglia MP, et al. Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol 2001;19:2821-8. https://doi.org/10.1200/JCO.2001.19.11.2821
  7. Bradfield SM, Douglas JG, Hawkins DS, Sanders JE, Park JR. Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma. Cancer 2004;100:1268-75. https://doi.org/10.1002/cncr.20091
  8. Casey DL, Kushner BH, Cheung NK, Modak S, LaQuaglia MP, Wolden SL. Local control with 21-Gy radiation therapy for high-risk neuroblastoma. Int J Radiat Oncol Biol Phys 2016;96:393-400. https://doi.org/10.1016/j.ijrobp.2016.05.020
  9. Ferris MJ, Danish H, Switchenko JM, et al. Favorable local control from consolidative radiation therapy in high-risk neuroblastoma despite gross residual disease, positive margins, or nodal involvement. Int J Radiat Oncol Biol Phys 2017;97:806-12. https://doi.org/10.1016/j.ijrobp.2016.11.043
  10. Gatcombe HG, Marcus RB Jr, Katzenstein HM, Tighiouart M, Esiashvili N. Excellent local control from radiation therapy for high-risk neuroblastoma. Int J Radiat Oncol Biol Phys 2009;74:1549-54. https://doi.org/10.1016/j.ijrobp.2008.10.069
  11. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77. https://doi.org/10.1200/JCO.1993.11.8.1466
  12. Seif AE, Naranjo A, Baker DL, et al. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. Bone Marrow Transplant 2013;48:947-52. https://doi.org/10.1038/bmt.2012.276
  13. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999;341:1165-73. https://doi.org/10.1056/NEJM199910143411601
  14. Halperin EC. Long-term results of therapy for stage C neuroblastoma. J Surg Oncol 1996;63:172-8. https://doi.org/10.1002/(SICI)1096-9098(199611)63:3<172::AID-JSO7>3.0.CO;2-A
  15. Matthay KK, Atkinson JB, Stram DO, Selch M, Reynolds CP, Seeger RC. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Children's Cancer Group pilot study. J Clin Oncol 1993;11:2226-33. https://doi.org/10.1200/JCO.1993.11.11.2226
  16. Haase GM, O'Leary MC, Ramsay NK, et al. Aggressive surgery combined with intensive chemotherapy improves survival in poor-risk neuroblastoma. J Pediatr Surg 1991;26:1119-24. https://doi.org/10.1016/0022-3468(91)90686-N
  17. Casey DL, Kushner BH, Cheung NV, Modak S, LaQuaglia MP, Wolden SL. Dose-escalation is needed for gross disease in high-risk neuroblastoma. Pediatr Blood Cancer 2018;65:e27009. https://doi.org/10.1002/pbc.27009
  18. Haas-Kogan DA, Swift PS, Selch M, et al. Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. Int J Radiat Oncol Biol Phys 2003;56:28-39. https://doi.org/10.1016/S0360-3016(02)04506-6
  19. Pai Panandiker AS, McGregor L, Krasin MJ, Wu S, Xiong X, Merchant TE. Locoregional tumor progression after radiation therapy influences overall survival in pediatric patients with neuroblastoma. Int J Radiat Oncol Biol Phys 2010;76:1161-5. https://doi.org/10.1016/j.ijrobp.2009.03.068
  20. LaQuaglia MP, Kushner BH, Heller G, Bonilla MA, Lindsley KL, Cheung NK. Stage 4 neuroblastoma diagnosed at more than 1 year of age: gross total resection and clinical outcome. J Pediatr Surg 1994;29:1162-6. https://doi.org/10.1016/0022-3468(94)90301-8
  21. Casey DL, Pitter KL, Kushner BH, et al. Radiation therapy to sites of metastatic disease as part of consolidation in highrisk neuroblastoma: can long-term control be achieved? Int J Radiat Oncol Biol Phys 2018;100:1204-9. https://doi.org/10.1016/j.ijrobp.2018.01.008
  22. Li R, Polishchuk A, DuBois S, et al. Patterns of relapse in high-risk neuroblastoma patients treated with and without total body irradiation. Int J Radiat Oncol Biol Phys 2017;97:270-7. https://doi.org/10.1016/j.ijrobp.2016.10.047
  23. Mazloom A, Louis CU, Nuchtern J, et al. Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma. Int J Radiat Oncol Biol Phys 2014;90:858-62. https://doi.org/10.1016/j.ijrobp.2014.07.019
  24. Polishchuk AL, Li R, Hill-Kayser C, et al. Likelihood of bone recurrence in prior sites of metastasis in patients with highrisk neuroblastoma. Int J Radiat Oncol Biol Phys 2014;89:839-45. https://doi.org/10.1016/j.ijrobp.2014.04.004
  25. Sibley GS, Mundt AJ, Goldman S, et al. Patterns of failure following total body irradiation and bone marrow transplantation with or without a radiotherapy boost for advanced neuroblastoma. Int J Radiat Oncol Biol Phys 1995;32:1127-35. https://doi.org/10.1016/0360-3016(95)00011-M
  26. George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem autologous peripheralblood stem cell-supported transplantation: long-term survival update. J Clin Oncol 2006;24:2891-6. https://doi.org/10.1200/JCO.2006.05.6986

Cited by

  1. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification vol.39, pp.1, 2019, https://doi.org/10.1186/s40880-019-0409-1
  2. Proton Beam Therapy for Children With Neuroblastoma: Experiences From the Prospective KiProReg Registry vol.10, 2021, https://doi.org/10.3389/fonc.2020.617506